Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Market Cap	$857.77M	P/E Ratio	N/A
52W High	$5.10	52W Low	$2.71
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	22.9%	52W Position	83.7%
Overall Score	58	Value Score	40
Quality Score	44	Technical Score	90

EPS Current Est	$-0.19	EPS Next Est	$-0.16
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ABUS	$4.71	+0.86%	1.57M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ABUS	$4.71	+0.9%	1.57M
3
4
5
6

ABUS

ABUS

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Arbutus Biopharma Corporation Data in Excel

Get Arbutus Biopharma Corporation Data in Excel